UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.
MeiraGTx, a US-based developer of treatments for genetic disorders backed by the UCL Technology Fund, floated on Nasdaq on Friday after raising $75m in an initial public offering.
The company priced 5 million shares at $15 each. The $75m figures fell short of the company’s initial target of $86.3m, which had briefly been raised to $92m.
MeiraGTx is working on gene therapy treatments that target inherited retinal diseases, neurodegenerative conditions and serious forms of xerostomia, also known as dry…
